2019 closes the year with 251 digital health fundings

thumbnail

Bright Health

Series D

$635.00

NEA, Bessemer Venture Partners, Cross Creek Advisors, Declaration Partners, Flare Capital Partners, Greenspring Associates, Meritech Capital, Redpoint Ventures and Town Hall Ventures.

Bright Health said that the new funds would fuel its continued expansion of products, regions and users. The startup will do so through new hires and continued work on its tech platform.

Through individual, family and Medicare Advantage plans, members can access services such as a health rewards program or personalized care teams through a consumer-minded tech platform consisting of web tools and a mobile app.

Q4

Babylon Health

Series C

$550.00

Saudi Arabian crown prince, Tencent, Samsung, Telus, Prudential Asia

This investment is part of Babylon Health’s recent fundraising to expand in North America, the Middle East and China.

Babylon’s app lets patients book virtual GP appointments and order prescriptions in order to make healthcare more accessible.

Q3

Clover Health

N/A

$500

Greenoaks Capital

The new money will be used for growth, innovation and deepening ties with physicians.

 

Q1

Gympass

N/A

$300

SoftBank’s Vision Fund Latin America Fund, General Atlantic, Atomico, Valor Capital Group

The new funding will allow Gympass to further personalize the user experience of its product. The startup also told Bloomberg that it will be expanding its service into the Asian region.

Gympass allows employers to provide employees with monthly passes that can be redeemed for gym access and various fitness classes. Through the app, members can search for locations that support a Gympass, lookup specific class schedules and check into their session via GPS.

Q2

Tencent Trusted Doctor

N/A

$250

Country Garden Holdings, Tencent Holdings and Sequoia Capital

N/A

Tencent Trusted Doctor said it connects 440,000 certified doctors with more than 10 million patients online, offering services from online consulting to e-commerce to physical checks.

Q2

Collective Health

Series E

$205

SoftBank, PSP Investments, DFJ Growth, G Squared, Founders Fund, GV, Maverick Ventures, Mubadala Ventures, NEA and Sun Life

Collective Health is targeting new strategic partnerships within the US; bumping up its sales, engineering and customer experience teams; and developing new capabilities to its platform.

Promising an alternative to hectic multi-vendor implementations, Collective Health’s suite of software offers a centralized hub for employers to manage members, conduct administrative tasks, optimize networks and point solutions, and gauge performance. Members, meanwhile, have access to an online and mobile portal that handles benefit navigation and, with the help of predictive analytics, matches members to the programs that would most benefit them.

Q2

iFIT

N/A

$200.00

Pamplona Capital Management

Watterson said that the investment will “allow iFit to further accelerate its rapidly growing interactive fitness platform in the connected home and club fitness industries.”

iFit — which shares its parent company with workout machine makers NordicTrack, ProForm and Freemotion — has built a streaming platform for use on these companies’ products. Users can sign up for individualized virtual workouts and classes led by live trainers.

Q4

Capsule

Series C

$200.00

TCV, Thrive Capital and Glade Brook Capital

The startup plans to put the new cash towards building its New York services and expanding to other locations.

The digital pharmacy company offers hand-delivered same-day medication drop off to its customers.

Q3

Doctolib

N/A

$170.30

General Atlantic, Eurazeo, Bpifrance, Kernel, Accel and unnamed German healthcare entrepreneurs

The company plans to use the funds to accelerate growth in France and Germany (it plans to double the size of its team over the next three years) as well as push into other international markets. Additionally, it will use funds for product development and to promote its telehealth offering, which just launched last month.

Doctolib offers its subscription-based SaaS platform to medical practices, allowing doctors to manage their appointment bookings and communicate with patients. The company also offers its services to patients, which they can use to to locate doctors or services while tracking their appointments.

Q1

Hims

N/A

$100

Undisclosed

Undisclosed

Hims is an online mail-order men’s health company that uses remote consultation to prescribe cosmetic and sexual health products.

Q1

DocPlanner

Series E

$90.90

One Peak Partners, Goldman Sachs Private Capital Investing, Piton Capital and ENERN Investments

The company said that it would use the new funding to continue its push in core European and Latin American markets, purse R&D activities and expand its team.

DocPlanner’s online doctor booking services offers doctors and clinics a SaaS tool to improve patient flow and help digitize their practices, and allows patients to book appointments through its online marketplace with healthcare professionals.

Q2

Tonal

Series C

$90

The Growth Fund of L Catterton, Evolution Media, Shasta Ventures, Mayfield, Serena Ventures and Sapphire Ventures

The company plans to use the new funding to create new “personalized software experiences” for the device, hire new talent and expand its video content library.

Tonal offers a special connected exercise machine with a AI-powered fitness software, all focused on the goal of strength training. Rather than traditional weights, the machine uses “digital weights” that use magnetic force to provide resistance.

Q2

Calm

Seires B

$88

TPG Growth, Creative Artists Agency and Insight Venture Partners and Sound Ventures

The company plans to use the money to build international growth.

The company created a guided meditation app.

Q1

Ro

Series B

$85

N/A

The company did not disclose its plans for the new money.

Ro made a name for itself in the digital health world with its online platform that specializes in men’s health, but has recently expanded to smoking cessation and women’s health.

Q2

Omada Health

N/A

$73

Wellington Management Company, Cigna Ventures, Andreessen Horowitz, U.S. Venture Partners, Norwest Venture Partners, Kaiser Permanente Ventures, Sanofi Ventures, Civilization Ventures and Providence Ventures

The funding will help ongoing scaling efforts for its digital care program.

Omada offers a slew of digital coaching programs addressing hypertension, Type 2 diabetes, mental health conditions and other health needs. The company also implements connected technology to track participants and hold them accountable — for instance, a wireless scale, a pedometer, and a mobile app to track food and activity for its diabetes program.

Q2

Weave

Series D

$70.00

Tiger Global Management, Catalyst, Bessemer, Crosslink, Pelion and LeadEdge

Weave wrote in its announcement that it’s aiming for a deeper push into the international markets, and will also be continuing its investment into product expansion and workforce development.

Weave’s digital platform looks to encompass a broad range of patient communications and relations capabilities for small to medium-sized practices.

Q4

Jawbone Health

N/A

$65.40

N/A

The company did not disclose specific directions for its new funding.

Jawbone Health sees itself as “a personalized subscription service that utilizes continuous health information combined with human and machine intelligence to take care of its members on a daily basis.”

Q2

Cityblock

Series B

$65

Redpoint Ventures, 8VC, Echo Health Ventures, StartUp Health, Sidewalk Labs, Thrive Capital, Maverick Ventures, Town Hall Ventures and EmbelmHealth

The company will use the new money to expand the team and grow its reach into both existing and new markets. It also plans to invest in technical product capabilities and add new services.

Cityblock, a spinout of Alphabet subsidiary Sidewalk Labs, looks to limit disparities by providing preventative medicine and access to resources through its digital tools.

Q2

Pear Therapeutics

Series C

$64

Temasek, Novartis, 5AM Ventures, Arboretum Ventures, Jazz Venture Partners, The Bridge Builders Collaborative and EDBI

The new money is set to help the company globalize the commercialization of the reSET suite of products—which were first commercially launched in November.

The Boston-based company makes prescription software-based treatments

Q1

Quartet Health

Series D

$60.00

Echo Ventures and Deerfield Capital

Quartet’s full Series D round aims to fuel the company’s expansion efforts. Of note, the company said during the summer that it hopes to reach Medicaid beneficiaries who are in need of behavioral health services.

Quartet’s integrated platform links providers, payers and services together in its aim to more effectively deliver mental and primary care.

Q4

Healthy.io

Series C

$60.00

Corner Ventures, Joy Capital Ventures, Ansonia Holdings, Aleph and Samsung NEXT

Healthy.io is accelerating global expansion and continue product development. Additionally, the company plans to pursue additional regulatory approvals so that its new ACR test can be used at home as well.

Healthy.io’s primary product is Dip.io, a smartphone-enabled testing kit consisting of a disposable test strip, testing cups and a colored panel. Strips are dipped into urine samples and then placed into the board, whereupon the user takes a picture of the two with their smartphone camera to receive a prompt result.

Q3

Quartet Health

Series D

$60

Centene Corporation, F-Prime Capital Partners, GV, Oak HC/FT and Polaris Partners

The latest round will support Quartet’s ongoing expansion, with a particular focus on Medicaid beneficiaries who are in need of behavioral health services.

Quartet’s integrated platform links providers, payers and services together in its aim to more effectively deliver mental and primary care.

Q2

PathAI

Series B

$60

General Atlantic, General Catalyst and others

The funding will help PathAI pursue new partnerships and build out its existing and in-development service offerings.

PathAI’s platform employs convolutional neural networks in its analysis of medical images. By doing so, the company’s product can help pathologists diagnose and sub-type cancer and other diseases.

Q2

Noom

Series E

$58

Sequoia Capital, Aglae Ventures, Samsung Ventures, and a number of individual investors including Whats App cofounder Jan Koum, DoorDash cofounder Tony Xu, and Oscar Health cofounder Scooter Braun

The new funding is expected to help the company grow their team and build their customer service capabilities.

Noom’s platform is focused on creating behavioral health changes related to weight loss, fitness and diet management.

Q2

Healx

Series B

$56.00

Atomico, Intel Capital, Global Brain, btov Partners, Balderton Capital, Amadeus Capital Partners, and Jonathan Milner

The funds will be used to develop the company’s therapeutic pipeline and to launch its global Rare Treatment Accelerator, a collaboration programme which allows select patient groups and clinicians to combine knowledge, information and expertise.

The UK-based firm specialises in using artificial intelligence to accelerate the discovery and development of rare disease treatments.

Q4

Whoop

Series D (includes debt financing)

$55.00

Foundry Group, Two Sigma Ventures, Accomplice, Thursday Ventures, Promus Ventures, Silicon Valley Bank and other individual investors

The $55 million will be put towards expanding consumer acquisitions, membership services and product development.

Whoop’s product includes a wearable strap that collects physiological data and a corresponding app, which gives users insights into their training and recovery.

Q4

Nurx

Series C

$52.00

Kleiner Perkins Digital Growth Fund, Union Square Ventures, Reproductive Health Investors Alliance, Dreamers VC (actor Will Smith’s venture fund), Lowercase Capital, and Y Combinator

The company has a lot of plans for this funding, including introducing additional offerings for what they describe as “sensitive health needs” and growing their userbase.

Nurx offers telemedicine prescription and delivery of birth control pills.

Q3

OM1

Series C

$50.00

Scale Venture Partners, General Catalyst, Polaris Partners and 7wire Ventures

OM1 said it will be using the funds to further flesh out its products for real-world evidence, value-based care and predictive medicine.

OM1’s cloud platform employs AI machine learning organize and analyze large datasets for real-world measures of clinical outcomes. Stakeholders across the healthcare industry can use the startup’s tools to support decisions regarding care management, treatment costs, regulatory submissions and event prediction.

Q4

Viz.ai

Series B

$50.00

Greenoaks, Threshold Ventures, CRV, GV and Kleiner Perkins

The new money will be put towards expanding the technology to more locations.

Viz.ai focuses on using AI to triage stroke patients and coordinate care. Specifically, using a deep learning algorithm the technology aims to highlight suspected large vessel occlusion. The system then alerts all members of the stroke team.

Q4

Talkspace

Series D

$50

Revolution Growth, Northwest Venture Partners, Qumra Capital, Spark Capital and Compound Ventures

The new funding will be put towards expanding Talkspace’s services and accelerating the startup’s commercial business. The company also noted that it plans to expand into international markets and build out new artificial intelligence capabilities.

Talkspace is a digital platform that connects patients seeking mental health services to providers. Based on a client’s needs, the platform matches them to a therapist. Users can then access clinicians through a telemedicine service and schedule times to talk.

Q2

Cala Health

Series C

$50

Novartis, Baird Capital, LifeSci Venture Partners, TriVentures, JJDC, Lux Capital, Lightstone Ventures, Action Potential Venture Capital, dRx Capital, GV and other unnamed backers.

The funding will kickstart the market launch of Cala Trio, its wearable hand tremor therapy, as well as buff up its therapeutic pipeline.

Stanford University spinout Cala Health has created a wearable neuromodulation therapy indicated for essential tremor, with other offerings under development focused on neurology, cardiology and psychiatry.

Q2

EverlyWell

Series A

$50

Goodwater Capital, Highland Capital Partners, Next Coast Ventures, NextGen Venture Partners and other unnamed investors.

The company will be using the $50 million to further expand its digital platform and beef up its partnerships with brands like CVS and Humana.

EverlyWell offers consumers a range of lab tests that can be ordered on the company’s website. Customers receive an breakdown of their results online.

Q2

Paige

Series B

$45.00

Healthcare Venture Partners, Breyer Capital, Kenan Turnacioglu and other funders

The company said the new cash will be put towards getting FDA clearance for its products and further development. The company is also looking to build up its commercialization in the US as well as expand to the European, Brazilian and Canadian markets.

The AI company uses computational and digital pathology to help oncologists and pathologists make decisions faster, more accurately and at a lower cost.

Q4

Teckro

Series C

$43

Northpond Ventures, Section 32, Founders Fund, Sands Capital Ventures and Borealis Ventures

The company will continue development of its platform and international expansion.

Teckro’s digital offering collects and conveniently presents clinical trial data within a single mobile platform. The machine learning-powered app keeps study teams and active trial participants connected and, as a result, allows stakeholders to conduct their trials more quickly and accurately.

Q1

Solera Health

Series C

$42

HCSC Ventures, BlueCross BlueShield Venture Partners/Sandbox Advantage Fund, Adams Street Partners and SJF Ventures

Solera will be using the funds to “extend the impact of its novel marketplace and payment innovation model.” In particular, the company noted its interest in addressing behavioral health and social determinants of health issues for its customers.

Solera’s platform hosts a broad selection of digital behavior modification programs that are offered to the members of its health plan and employer customers.

Q2

Elvie

Series B

$42

IPGL, Octopus Ventures and Impact Ventures UK.

The new money will be put towards research and development, as well as growing brand awareness for the two products in the Americas, Europe and Asia.

The women-led startup has developed two main products in the feminine care space; a pelvic floor trainer and a breast pump.

Q2

OneDrop

Series B

$40.00

Bayer

While the company didn’t spell out exactly how they will be using the $40 million, its new deal with Bayer includes helping the pharma build up its digital efforts in oncology, cardiovascular diseases and women’s health.

OneDrop uses artificial intelligence to make lifestyle recommendations to people with chronic conditions.

Q3

Aidoc

Series B

$40

Square Peg Capital

Aidoc is looking to extend its reach to more providers.

Aidoc’s FDA-cleared and CE-marked solutions support and enhance the impact of radiologist diagnostic power, helping them expedite patient treatment and improve quality of care.

Q2

TriNetX

Series D

$40

Merck Global Health Innovation Fund, Mitsui & Co. and Itochu Technology Ventures, MPM Capital, F2 Ventures and Deerfield Management

The $40 million will support the TriNetX’s expansion in Europe, Asia and South America. Additionally, the company is looking to continue developing the AI, machine learning and digital clinical trial components of its analytics platform.

TriNetX has built a data platform containing clinical and claims information generated from more than 300 million global patients. The company provides these real-world data to clinical researchers on demand alongside supporting analytics tools.

Q1

EarlySense

N/A

$39

Hill-Rom and Wells Fargo & Company, BlueRed Capital, Israel Innovation Fund, Argos Capital and Hotung Capital

The company hinted that this new money will be used to expand AI analytics and grow sales both internationally and domestically.

EarlySense makes a contact free health monitoring system.

Q1

Synyi

Series C

$36.30

Tencent, Sinopharm Capital

Synyi will use the latest funds to explore the smart healthcare sector, attract new medical and AI talent and ensure its products stay at the top of the Chinese market.

To solve the problem of data silos and low usability of data in healthcare information systems, Synyi developed a new hospital informatics platform with AI capabilities in 2018.

Q3

Bardy Diagnostics

Series B

$35.50

River Cities Capital Funds, HealthQuest Capital, Aperture Venture Partners, Aphelion Capital, Lumira Ventures, Rex Health Ventures, V Health Investors, Health Enterprise Partners and Ascension Ventures

Bardy Diagnostics will be leveraging the funds to expand its sales force and monitoring services, pursue development of augmented intelligence and visualization capabilities, and generally fuel the growth of its platform.

Bardy Diagnostics’ primary product is the Carnation Ambulatory Monitor (CAM), a P-wave signal-capturing wearable that can be used to remotely monitor patients’ cardiac activity or detect arrhythmia over a seven-day period.

Q2

Exo

 

$35.00

Intel Capital, Applied Ventures, Bold Capital, Creative Ventures, Longevity Vision Fund, Magnetar Capital, Nautilus Venture Partners, OSF Healthcare, Rising Tide Fund, Sony Innovation Fund and Wanxiang Healthcare Investments

The new money will be put towards developing the product and helping the startup go through regulatory channels.

The Redwood City, California-based startup is developing a portable ultrasound that is able to create a 3D image.

Q3

Ginger

Series C

$35.00

WP Global Partners, City Light Capital, Nimble Ventures, LinkedIn CEO Jeff Weiner, Khosla Ventures, Kaiser Permanente Ventures and Kapor Capital

The new money will go toward growing its data sciences and clinical services. It is planning to expand globally within the next two years.

Ginger focuses on providing digital mental health services including behavior health coaching, video therapy, tele-psychiatry visits and other self-guided content.

Q3

Biofourmis

Series B

$35

Sequoia India, MassMutual Ventures, EDBI, Jianke, Openspace Ventures, Aviva Ventures and SGInnovate

The company plans to use the new funds to commercialize in the US and Asia and grow its team focused on data science, clinical and regulators and sales operations.

Using a propriety wearable, a patient-facing app and AI technology, the system is able to create digital biomarkers “reflecting the health status” of a patient. The platform was designed to detect when an adverse health event is about to happen. In part, the system was created to help monitor patients as they take different medications.

Q2

Unite Us

Series B

$35

Oak HC/FT, Newcomers Town Hall Ventures, Define Ventures, Scout Ventures, Luminate and New York Ventures

The new funding will be used to fuel its continued growth and coordinated network curation.

Unite Us’ digital platform not only handles external referrals between community services and providers, but also tracks each patients’ outcomes and their journey through care. The company’s goal is to develop a unified support network able to address social determinants of health in ways that health systems or social service workers working alone could not.

Q1

Innovaccer

Series B

$35

Microsoft’s venture fund M12, Westbridge Capital and Lightspeed

The new money will be put towards growing its AI capabilites and growing its team.

Innovaccer’s product InData is a unified health data integration platform that offers providers a full view of a patient’s data, both insidea nd outside of thir network.

Q1

Diabeloop

Series B

$34.40

Odyssée Venture, Supernova Invest, Air Liquide Venture Capital and others

Diabeloop now plans to accelerate the commercial rollout of its system, ramp up R&D activities and submit its application for FDA clearance, having already obtained CE marking.

The company’s primary product is what is referred to as a hybrid closed-loop system for management of Type 1 diabetes. Called DBLG1 (Diabeloop Generation 1), it connects a continuous glucose monitor, a patch insulin pump and a handset that hosts the company’s unique algorithm.

Q4

Mirror

Series B-1

$34.00

Point72 Ventures, lululemon, LionTree LLC, Spark Capital and individual backers, including Karlie Kloss, Kevin Huvane, Lerer Hippeau and Steve Lockshin.

Mirror said that it will use the funds to sustain strong growth momentum, as well as to push into different types of content verticals.

The core of the startup’s platform is a large LCD panel that streams workout videos and music, while also doubling as a full-length mirror when not in use.

Q4

Limelight Health

Series C

$33.50

Principal Life, AXA Venture Partners, MassMutual Ventures, Aflac Ventures, Transamerica Ventures, Wells Fargo Strategic Capital, LaunchPad Digital Health and Wanxiang America Healthcare Investments.

Limelight will be using its new capital to support customer acquisition, staffing and global expansion.

Limelight’s cloud-based software looks to streamline quoting and underwriting for medical and ancillary carriers handling employee benefit plans.

Q1

Alodokter

Series C

$33.00

Sequis Life, Philips, Heritas Capital, Hera Capital, Dayli Partners, Softbank Ventures Asia and Golden Gate Ventures

Alodokter will use the funds to expand its hospital network integration and to further develop its health insurance service.

Halodoc operates a mobile platform for patients to access doctors any time of the day and pharmacy delivery across 50 cities, as well as home lab services, increasing accessibility to easy, affordable, and reliable healthcare services.

Q4

DispatchHealth

N/A

$33

Echo Health Ventures, Alta Partners, Questa Capital and other unnamed backers

The Denver, Colorado-based startup plans to put these new funds towards opening up new locations across the US.

DispatchHealth’s platform allows patients to request on-demand care to their home. Clinicians will arrive to the patient’s home within two hours of the request and can treat flu, UTI, stomach virus, respiratory conditions and other common health concerns.

Q2

Redox

Series C

$33

Battery Ventures, .406 Ventures, RRE Ventures and Intermountain Ventures

The round will help the company expand its reach and improve its user experience.

Redox focuses on data interoperability for health apps and other health IT services.

Q2

Amboxx

Series B

$32.90

Partech’s growth fund, Cherry Ventures, Wellington Partners and Holtzbrinck Digital

The new funds will go toward developing clinical decision support tools for specialists and generalists.

Amboss was developed as a digital resource to help medical students and professionals access information. The platform includes a program specifically designed help medical students study for the US medical licensing exams and national board exams.

Q3

Zava

Series A

$32

HPE Growth

The company will be using these funds to accelerate its growth.

Zava is a London-based telemedicine provider active across six European markets.

Q2

DayTwo

Series B

$31

Ofek Ventures, aMoon led the round, Seventure Partners and Johnson & Johnson.

The money will fuel its push into the US market, where it will be seeking partnerships with payers, providers and large employers. In addition, DayTwo will be targeting new products and services focused on metabolic and gastrointestinal conditions.

DayTwo’s platform asks patients to send a sample of their gut microbiome to the company’s lab, where it is sequenced and characterized alongside blood test results and a user questionnaire. These results are delivered back to the patient as a full report of their gut health, and read by a machine learning algorithm that, through an app, provides the patient with meal scores as well as prediction of how certain food will affect them.

Q2

Huimei Healthcare

Series C

$30.00

Qiming Ventures and WuXi AppTech

The funds will be used by the company to develop its core-product, as well as for further product R&D.

Huimei Healthcare’s core product is an AI-based clinical decision support system called Dr. Mayson.

Q3

Vida Health

Series C

$30

GuideWell Mutual Holding Corporation, Teladoc Health, Workday Ventures, unnamed prior backers

Vida plans to scale its sales, marketing and recruiting coaches for platform expansion.

Vida Health offers multifaceted systems for managing a number of physical and behavioral chronic conditions. The offering includes digital therapeutics, digital communication with live health coaches and, in many cases, connected devices which send biometric data to coaches and apps.

Q2

Carbon Health

Series B

$30

Brookfield Growth Partners, DCVC, Builders VC, Bullpen Capital, Javelin Venture Partners and Two Sigma Ventures

The company said that the funding will be put towards breaching into new markets nationwide. In a statement, the company also noted that it would be using the funds to grow its consumer retail capabilities.

Carbon is a hybrid of digital and in-person care service. Patients using the service can book an appointment at an urgent or primary care facility in its network. Currently all of the in-person facilities are located in the San Francisco Bay Area.

Q2

LetsGetCheck

Series B

$30

LTP, Optum Ventures, Qiming Venture Partners USA

LetsGetChecked will continue to scale its consumer-facing brand. In addition, the company will also be expanding its North America manufacturing and logistical capabilities, and further developing its core technology.

The New York City-based company offers consumers a range of lab tests that can be ordered through an online site or partner retailers. Customers receive a kit in the mail, which instructs them how to collect and return a sample to the company, and can view their results and consult through an app.

Q2

CareStack

N/A

$28.00

Steadview Capital and Delta Dental of California

The new infusion of capital will go towards expanding CareStack’s customer base and expanding its services to more dentists.

The company focuses on workforce and clinical management for dental practices. The platform includes access to a patient portal, scheduling capabilities, business analytics, claims data, billing information, charting and patient engagement tools.

Q4

Calm

Series B

$27.00

Lightspeed Venture Partners

The comapny did not outline plans but previously discussed international growth.

Calm is mainly a meditation app. It has added new features to include a breathing coach and tools for helping users fall asleep.

Q3

Aetion

Series B

$27

Sanofi, UCB, McKesson Ventures, Horizon Health Services, NEA, Flare Capital and Lakestar

The new funds will be put toward improving the Aetion Evidence Platform.

The company aims to help payers and providers collaborate in real-time with pharma and device companies as they develop, test and launch new therapies

Q1

MDClone

Series B

$26.00

aMoon, OrbiMed Israel Partners and Lightspeed Venture Partners

The company will use the funds to further develop its existing platform, build new products and accelerate growth.

MDClone’s engine examines original patient data and generates new datasets based only on statistical data, containing no information that would risk exposing patient identity.

Q3

CirrusMD

Series B

$26

Drive Capital, the Colorado Impact Fund and other existing investors

The company hasn’t been exceptionally specific about plans for the funding, saying only that it will support their next phase of growth as well as product innovations and existing and new partnerships.

CirrusMD is part of a smaller group of telemedicine companies that believe text-based chat, not video, is the most efficient and effective vector for telemedicine.

Q2

Medopad

Series B

$25.00

Leaps by Bayer

The company plans to use the new funds to focus on its R&D projects and partnerships, and to break further into digital therapeutics development.

The company uses AI to collect and analyze data and then predict different medical conditions and outcomes. Clinicians can tap into an app and web platform to look at various biometric data points and access additional resources.

Q4

Rapid SOS

Series B add-on

$25.00

Energy Impact Partners

Rapid SOS said the new funds will help its efforts to develop partnerships with public safety agencies and public safety software providers.

The startup’s system integrates data from a variety of sources including from wearables, telematics from connected cars, smoke density from smart homes and location tracking phones, and connects them to 911 responders when there is an emergency.

Q4

BrightInsight

Series A

$25.00

New Leaf Venture Partners and Eclipse Ventures

This new round will help the company beef up the functionality of its platform as well as its commercialization efforts. In addition, BrightInsight is seeking to further its integration with EHRs, payers and disease management platforms.

BrightInsight — part of electronics manufacturing services firm Flex —sees itself acting as the infrastructure of a digital health ecosystem. Its Internet of Things platform brings together assorted digital health products and services so that provider, biopharma or other healthcare organizations can more easily manage their data.

Q3

Phil

Series B

$25

GreatPoint Ventures, Tarsadia Investments, Crosslink Capital and Uncork Capital

The new money will be put towards the company’s growth, with a focus on hiring technical talent and increase its global footprint.

The platform pitches itself as a way to automate physician, payer pharmacy workflows while helping patients schedule refills.

Q2

AiCure

Series C

$24.50

Palisades Growth Capital, Singtel Innov8, Asahi Kasei Corporation, Accelmed Growth Partners, SpringRock Ventures and existing institutional investors

The AI company said in its announcement that the funds will help “accelerate commercial, engineering, and research and development activities in order to advance research-grade data insights for life science companies.”

AiCure’s interactive medical assistant, or IMA, collects visual and audio data from patients to quantify their engagement with a treatment program, allowing the tool to identify patients who are at higher risk of dropout or non-adherence.

Q4

Vim

Series B

$24.00

Optum Ventures, Premera Blue Cross, Great Point Ventures, Sequoia Capital and Leverage Health Solutions

The new funding will support the company’s growth as it enters new markets within the US. It also plans to scale up its product development and hiring initiatives.

Vim offers a patient-facing appointment booking platform that can be integrated onto payer and provider sites or apps.

Q3

GNS Healthcare

Series D

$23.00

Cigna Ventures, Amgen Ventures, Celegene, Echo Health Ventures, Alexandria Venture Investments and Gary Loveman, the former CEO of Caesar and division president of Aetna

While the startup didn’t spell out its exact intentions for the money in the future, it did indicate that it would be working with Cigna and others to continue personalized health iniatives.

The company’s platform, dubbed REFS (Reverse Engineering and Forward Simulation), is able to collect multiple data points — including a patient’s EHR data, lab results, genomic data, and prescription data — and in turn help pinpoint relationships between outcomes and treatment.

Q3

Genome Medical

Series B

$23

Echo Health Ventures, LRVHealth, Casdin Capital, Perceptive Advisors, Manatt Venture Fund, Dreamers Fund, Canaan Partners, GE Ventures, Illumina Ventures, Kaiser Permanente Ventures and HealthInvest Equity Partners

The company will be expanding its team of specialists and increasing development of its platform to prepare for further scaling of its services.

Genome Medical offers providers, payers and employers with a cloud-based “telegenomics” platform. Through it, patients can schedule virtual visits with genetic experts that can deliver counseling, education and other guidance, while providers can arrange for an expert consultation.

Q2

Lifen

N/A

$22.70

Partech, Idinvest Partners, Mayjcc eSanté, Serena, Daphni

Lifen will be accelerating deployment of its solution and doubling its team.

The commmunications platform aims to enable healthcare organizations and private practitioners exchange medical data securely.

Q2

Avia

N/A

$22.00

First Trust Capital Partners, Sumitomo Corporation of Americas and Ziegler

The latest funds will be put towards expanding its services into new digital areas. In particular the new money will go towards its efforts in understanding consumer health and how digital can be used in Medicaid, virtual health and automated tools.

The company works with healthcare providers and other stakeholders to help organizations analyze digital tools and understand how those tools will impact finances and clinical care. The service works with its clients to get an overview of the market, set up goals, evaluate solutions and drive adoption.

Q4

Kheiron Medical Technologies

Series A

$22.00

Atomico, Connect Ventures, Greycroft, Hoxton Ventures and EXOR Seeds

Kheiron plans to use the new funding to carry out further clinical trials of Mia in Europe, the US and Asia in order to “rigorously assess and demonstrate the clinical effectiveness and safety of the software,” according to a press announcement.

Kheiron’s Mammography Intelligent Assessment is designed to analyse standard full-field digital mammography (FFDM) images in a breast cancer screening setting and support radiologists in making the clinical decision to recall a patient for further investigation or not.

Q3

Cardinal Analytx

Series B

$22

Kleiner Perkins’ John Doerr, GuideWell Mutual Holding Corporation, Blue Shield California and Premera Blue Cross

The money will be invested in new employees and technology that will help the company grow its machine learning and predictive model.

The Stanford University spinout was founded with the goal of providing predictive population health insights. The company’s tool uses artificial intelligence to predict which patients will have high health spending in the future. It then sets its clients, insurers and providers up with plans to intercept and help patients before their conditions deteriorate.

Q2

Aduro

N/A

$22

Abry Patners

The new money will be used to help the company scale its product and grow globally.

Aduro is a wellness platform that teams up with employers and other organizations to motivate members to stay active and healthy

Q1

KenSci

Series B

$22

Polaris Partners, Osage University Partners and Mindset VEntures

The West Coast startup said that the new money will be put towards accelerating the company’s “roadmap” and to expanding globally.

KenSci uses machine learning and artificial intelligence to identify patterns and health risks. It is able to ingest data from multiple sources including EHRs, claims statements, pharmacy history and wearable data. The company said the goal is to improve care and lower its cost.

Q1

Neurotrack

Series C

$21

Khosla Ventures, Dai-ichi Life, SOMPO holdings, Sozo Ventures, Rethink Impact, AME Cloud Partners and Marc Benioff

The new money will be put towards commercializing Neurotrack’s Memory Health Program. The startup is also looking to expand into global markets.

Neurotrack’s platform was designed with the dual purpose of assessing memory loss and cognitive decline, as well as preventing these conditions from progressing.

Q2

Nomad Health

N/A

$20.37

Icon Ventures with participation from Polaris Partners, RRE Ventures, .406 Ventures and Silicon Valley Bank

The startup has pledged to use the new funds to double its staff and build out its technology.

The company’s digital platform aims to connect qualified doctors and nurses to provider organizations looking for new staff.

Q3

Rightway

Series B

$20.00

Thrive Capital

The new cash will be put towards expanding the platform and developing new products.

The two-year-old company’s product is a smartphone and web service that helps employees understand and utilize the health benefits available to them. Users are able to see both costs and care options available in their plan. The service includes real staff that can help users understand their benefits.

Q4

Eko

Series B

$20.00

ARTIS Ventures, DigiTx Partners, NTT Venture Capital (NTTVC), 3M Ventures, Mayo Clinic, Seaph Group and XTX Ventures

These new funds with support additional R&D and commercialization of its machine learning platform.

The San Francisco company is perhaps best known for its Eko Duo device, a smart remote monitor that’s part stethoscope, part ECG. However, the company has lately had a hand in the clinical trial space as well, having launched a new platform in July called Eko Home that looks to pinpoint novel drug-data combinations.

Q3

Hydrow

Series A

$20

L Catterton, Rx3 Ventures, Wheelhouse, The Raptor Group, The Yard Ventures

The new funding will help Hydrow grow its business and ship its first devices to early backers.

Often described as a “Peloton for rowing,” Hydrow’s device offers consumers an in-home rowing workout that is supported by live or on-demand digital courses.

Q2

Trusted Health

Series A

$20

Craft Ventures, Felicis Ventures, Founder Collective, Healthbox and Texas Medical Center

The funding will be used to keep pushing that expansion, with the goal of being in all 50 states and the District of Columbia. The company also wants to expand the list of available opportunities by building out capabilities to support different kinds of jobs, and to generally improve the technology.

Trusted Health has been building out, and rolling out, a technology platform that helps nurses find jobs and negotiate pay, helps them manage credentialing and paperwork and employs contract nurses as full W2 employees to ensure they get full benefits.

Q2

Augmedix

Series B

$19.00

Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments and other unnamed investors

Augmedix said the raise will support product developments such as automation, as well as the scaling of its service to systems and clinics across the country.

Using a Google Glass or smartphone, professional medical scribes can remotely observe the visit and, with the help of NLP, fill out the patient’s necessary documentation.

Q4

inveox

N/A

$18.50

N/A

The company did not disclose how the new money would be used.

inveox is the maker of an AI-enabled system developed to digitize processes in pathology laboratories.

Q3

Peerfit

Series C

$18

Virgo Investment Group

Peerfit will be using its new funds to expand its brand and lock down more employer customers. In addition, the company will also be continuing its pursuit of the Medicare Advantage market with Peerfit Move.

Peerfit’s standard employer-provided benefits platform offers both bulk and per-use token purchases, each of which is supported by an online dashboard to streamline class browsing and reservations, or send department-wide class invites to better engage employees. The service currently provides access to gyms and fitness studios across most US states.

Q1

Healthy.io

Series B

$18

Aleph, Samsung Next and private investors

The new money will be used to help scale operations in the US and continue roll out of services in the UK.

The company’s signature product is Dip.io, a home-based urinalysis kit that turns a smartphone into a clinical-grade diagnostic device.

Q1

Welkin

Series B

$17.50

Altos Ventures, Thrive Capital, Red Swan and Asset Management

The company plans to use the new money to expand both its team and product line.

Welkin was founded in 2013 with a focus on diabetes management but it quickly identified patient engagement workflow tools as a problem area in the space. Now the company focuses on helping its clients tackle issues related to patient engagement workflow.

Q2

mfine

Series B

$17.20

SBI Investment, SBI Ven Captial BEENEXT, Stellaris Venture Partners and Prive Venture Partners

The new funds will be used to expand its hospital network across the country, build its AI technology and expand the recently launched additional services.

 

Q2

Pivot

Series A

$17.00

DCM, Bling Capital, Founders Fund, Khosla Ventures, Signal Fire and Y-Combinator

It will be using the funds to bulk up its engineering and operations teams.

Pivot’s platform is a combination hardware and software service offering consisting of weights, a heart rate monitor, a connected mobile app and 3D sensors that use machine learning to track the user’s movements.

Q3

Ciitizen

Series A

$17

Andreessen Horowitz, Verily and Section 32

It will be using the new funding to continue building its platform and buff its commercial efforts.

The company aims to solve the many problems of healthcare data sharing and lack of interoperability by creating a patient-centered medical record.

Q1

Nines

Series A

$16.50

Accel and 8VC

While the company did not outline a specific plan for its funds, the announcement did note ongoing regulatory discussions with the FDA concerning its Emergent Neuro Suite software product.

The two-year-old startup’s efforts are broken into two camps. On the one hand is a tele-radiology service that’s staffed by live specialists, and the other is a machine learning platform to support image data analysis.

Q4

Luma Health

Series B

$16.00

PeakSpan Capital, Cisco Investments, Texas Medical Center and US Venture Partners

Luma plans to target larger customer organizations and hire new staff that could build out new patient acquisition and retention features for the platform.

Luma’s “end-to-end patient journey automation platform” is an EHR-friendly tool that eases patients into care while automating their booking and scheduling needs. The text-driven tool automatically reaches out to patients with appointment reminders, referral management, insurance data validation or general post-procedure check ins, while updating supported EHR or scheduling systems accordingly.

Q3

Lively

N/A

$16

Declaration Capital and Tiger Management

 

Lively specializes in connected hearing aids.

Q1

RxRevu

Series A

$15.90

UCHealth, University of Virginia LVG Venture Fund, Presbyterian Healthcare Services, Inception Health/Froedtert Health, Children’s Hospital Colorado, UnityPoint Health, JAZZ Venture Partners and existing investors

The new infusion of cash will be put towards growing the company’s platform and technology.

The company’s platform, called SwiftRX, uses machine learning to help doctors choose which medication to prescribe for their patient, keeping in mind health and financial factors. In addition to a patient’s current diagnosis, the platform will let clinicians see their patient’s medical history, insurance information, and out of pocket costs.

Q2

PathAI

Series B add-on

$15.00

Merck Global Health Innovation Fund and Bristol-Myers Squibb

PathAI said in the announcement that the additional funds will help the company push its clinical development capabilities. It will also cement the AI company’s relationship with Merck and BMS as they develop new cancer therapies with PathAI’s technology.

PathAI’s platform employs convolutional neural networks in its analysis of medical images. This allows the company’s product to help pathologists diagnose and sub-type cancer and other diseases. Further, PathAI’s technology can be used to assist in new drug development by identifying patients who may be candidates for a novel therapy.

Q4

Sensely

N/A

$15.00

Aflac Corporate Ventures, NMC, Nippon Life Insurance Company, Susquehanna International Group, Sojitz Corporation, Zuellig Pharma and Silicon Valley Bank

The new funds will be put toward growing the platform and market expansion. In particular, the company is looking to increase its multilingual platform.

Sensely uses avatars to help users understand and organize their insurance information. Users can send messages back and forth with the avatar. The system uses text-to-speech and speech recognition technologies.

Q4

Modern Fertility

Series A

$15

Forerunner Ventures’s Kirsten Green

Modern Fertility will be funneling the new capital into fertility science research to inform the addition of new offerings into its current product.

Modern Fertility’s direct-to-consumer business starts when the customer requests a personalized at-home test, or opts to take it at a local lab. Once the results are submitted and reviewed by a clinician, the results are communicated to the customer through a private dashboard housed within a smartphone app or online portal.

Q2

Forefront Telecare

Series A

$15

Tech Council Ventures and Boston Millennia Partners

The startup is planning to use its investment to grow its network of telepsychiatry providers, further develop HIPAA-compliant telehealth platform and push its business into new states.

Forefront Telecare specializes in providing virtual behavioral telehealth to seniors, and in particular targets Medicare patients in rural hospitals and skilled nursing facilities.

Q2

Kindbody

Series A

$15

RRE Ventures, Perceptive Advisors, Green D Ventures, Trail Mix Ventures and Winklevoss Capital

The company plans to expand into mental health, nutrition and gynecological services in the future. It is also opening a new, larger brick-and-mortar location in New York.

Kindbody offers women fertility testing, egg freezing, IVF and wellness care. In addition to the brick-and-mortar location in New York, where women can come for fertility treatments, patients can also access virtual care.

Q2

Medigate

Series A

$15

US Venture Partners YL Ventures and Blumberg Capital

Medigate said that it is planning to fuel the growth of its business, specifically through the pursuit of new hires.

Medigate builds a platform dedicated to securing networked medical devices that are connected to EHRs, device servers and other enterprise systems.

Q1

Maple

N/A

$14.50

Acton Capital and SE Health

Maple is looking to grow its services in Canada over the next two years, and said the new funds will help enable this.

Maple is a traditional virtual care company that connects patients to doctors through a telemedicine platform.

Q3

Belong.Life

Series B

$14.00

IQVIA, The Group Ventures and the startup’s existing vendors

The new funding will be used to expand its social network app and patient engagement platform.

The company’s free Belong app allows patients with cancer or those caring for them to connect with and support others undergoing treatment for dozens of different cancers.

Q3

Deep Lens

Series A

$13.70

Northpond Ventures, Rev1 Ventures, Sierra Ventures and Tamarind-Hill Partners

Deep Lens will leverage the new funding to scale its service, sales, and marketing teams, as well as to build upon its artificial intelligence and platform development.

Deep Lens allows pathologists to study a multitude of digitized bio specimen slides when making a cancer diagnosis.

Q2

Podimetrics

Series B

$13.40

Rock Health, Norwich Ventures and Scientific Health Development

The startup will be expanding its presence within the Department of Veterans Affairs as well as building upon its commercial payer business.

Podimetrics’ platform consists of a cellular-connected SmartMat for use in the home, and a corresponding clinician-facing dashboard. Users stand on the SmartMat for 20 seconds each day, during which the device collects foot temperature scans and transmits the results to the company’s care team.

Q2

HealthJoy

Series B

$12.50

US Venture Partners, Epic Ventures, Chicago Ventures, Sidekick Ventures and HealthJoy’s cofounders

The company will be looking to expand its team, both in the main Chicago office as well as abroad.

HealthJoy expanded its business from the individual health insurance market to employee engagement and cost containment in 2016. Key to the company’s approach is Joy, a virtual assistant that helps users understand their benefits packages and navigate their care options through an AI-guided conversation.

Q1

Hello Heart

Series B

$12.00

Khosla Ventures, BlueRun Ventures, Maven Ventures and Resolute Ventures

The money will be put towards expanding and scaling its team.

Hello Heart’s bread and butter is its app-driven platform for hypertension, blood pressure and general cardiovascular health management.

Q3

Current Health

Series A

$11.50

MMC Ventures, Legal & General, Par Equity and Scotting Investment Bank

The funding will be used to scale the company’s platform, hire new staff and improve the AI algorithm.

The primary device of Current’s monitoring platform is an FDA-cleared upper-arm wearable that tracks skin temperature, pulse rate, oxygen saturation, movement and other metrics. Patients using the platform receive the tracker alongside a tablet that provides a Q&A chatbot, educational content, medication reminders and support for video or text conversations with a clinician.

Q4

MedAdvisor

Strategic investment

$11.50

HMS Holdings and others

MedAdvisor said that it will be using the new cash to speed up international expansion into the US, Southeast Asia and the UK — an aim with which HMS can contribute.

MedAdvisor’s mobile and web platform provides users with a list of their medications that’s automatically updated when a script is filled. It includes information about each medication, such as instructions for use or warnings of possible side effects.

Q4

Robin Healthcare

Series A

$11.50

Northwest Venture Partners

Robin will put the new money towards developing its product and building relationships with more provider organizations.

Robin’s device, which looks similar to an Amazon Alexa or Google Home voice assistant, will sit in a doctor’s office and draft notes from clinicians’ spoken conversations. The voice-enabled AI device is designed to help doctors and clinicians write clinical notes.

Q3

Peerbridge

N/A

$11.00

Northwell Health, Ascent Biomedical Ventures, Olipan Investments and Kinled Holding

Peerbridge said in its announcement that it is looking to expand into additional reimbursement qualifications for its monitoring platform.

The startup’s primary offering is Peerbridge Cor, a multi-channel wireless ECG patch that is adhered to the chest. Cleared in 2017, the continuous monitoring device can be worn up to seven days, and is able to classify 26 types of arrhythmia indications.

Q4

Octave

Series A

$11.00

Greycroft and Obvious Ventures

Octave will be further expanding its physical presence in both California and New York next year, and plans to triple its number of on-staff providers “in the coming months.”

New York-based Octave is behavioral health therapy delivered in practice by a licensed psychologist or therapist, and digital coaching sessions offered via video chat.

Q4

Pillo Health

Series A

$11

Stanley Ventures, Samsung Ventures, BioAdvance, Hikma Ventures, Hackensack Meridien Health System’s Innovation Center Fund and Civilization Ventures

Pillo Health will continue to develop its technology platform, build new voice-based healthcare products for its various partners, support the upcoming US launch of Pria by Black + Decker and hire new employees for its Boston and Genoa, Italy offices.

Pillo Health’s lead product is the eponymous Pillo, a countertop artificial intelligence device that uses voice to engage users and remind them to take medications. Designed for older patients with chronic diseases or complex care plans, the tool can store, dispense and reorder up to 28 doses of medication on a pre-set schedule. In addition, Pillo can deliver audio- or video-based health content and facilitate video calls between patients and their caregivers, while allowing the latter to monitor adherence data generated from the device.

Q2

Xealth

Series A

$11

McKesson Ventures, Novartis, Philips and ResMed, Threshold Ventures, Providence Ventures, UPMC and Medical College of Wisconsin Health Network affiliate Froedtert

Xealth will primarily be using its latest investment to continue building out the platform.

Xealth’s digital health prescription platform allows physicians to prescribe a wide variety of apps or other digital health tools to their patients, as well as monitor patients’ engagement or progress. And, because the platform integrates with the provider’s wider IT system, patients and clinicians alike are are able to access these tools within their respective patient portals and EHR workflows.

Q1

FeetMe

Series A

$10.30

LBO France, Kurma Diagnostics, Paris Saclay, Idinvest Partners, Seventure and SOSV

This latest funding round will support the company’s as it fosters commercial activities in clinical trials and bolsters its healthcare services for hospitals and rehab facilities.

FeetMe’s sensor comes in the form of a shoe insole and includes both pressure and motion sensing technology. The system is also outfitted with an algorithm to help analyze a person’s walk.

Q4

Firefly Health

Series A

$10.20

F-Prime Capital and Oak HC/FT

While the company has not specified how the new money will be used, it did say that it plans to enter several new markets in 2020.

The platform helps connect members and medical service, whether that be in-person or digitally. Patients are able to see a provider in person, through video visits or via in-app chat, and manage prescription refills.

Q3

Papa

Series A

$10.00

Canaan, Pivotal Ventures, Initialized Capital, Y Combinator and Sound Ventures

Papa plans to use the new funds to expand its services through more partnerships with insurance plans and employee benefit providers. By next year, the company plans to be active in 25 states, and today’s news coincided with the announcement that Papa was teaming up with employer benefits provider New Benefits.

The Miami, Florida-based startup created a digital tool to link older adults in need of assistance with a college or nursing student.

Q4

Mednition

Series A

$10.00

Concord Health Partners

Proceeds from the financing will be used to expand the company’s customer care team as Mednition further scales commercial deployment of KATE.

Starting initially in the emergency department, Mednition is providing emergency nurses with KATE, a machine learning clinical decision support solution now in use at Adventist Health White Memorial in Los Angeles.

Q3

InsightRX

Series A

$10.00

HealthX Ventures, Rock Health, OSF Healthcare, Leawood Venture Capital, GreatPoint Ventures and Premier Inc.

This latest funding will help InsightRX push its platform into new therapeutic areas and improve system integrations. The company is also looking to expand its reach within the provider and pharmaceutical markets.

InsightRX has built a software platform that relies on EHR data to develop individualized medication dosing regiments. Called InsightRX Nova, physicians can employ the tool at the bedside to assist with treatments for more than 100 drug-assisted therapeutic areas.

Q3

Myia Labs

Series A

$10.00

Mercy Virtual, etta Venture Partners, BootstrapLabs, Boston Consulting Group and B Capital Group

This new investment will help it scale hiring efforts, particularly for roles relating to data science and mathematics, security and regulatory affairs. In addition, the funds will also fuel the product’s expansion from its initial focus on congestive heart failure to other chronic conditions such as COPD, Type 2 diabetes and hypertension.

Myia’s platform uses Apple Watches, Fitbits, Oura Rings and other consumer devices with monitoring capabilities to collect real-world patient data. These are combined with the company’s applied machine intelligence tech to generate insights on these patients’ chronic conditions.

Q3

Health Recovery Solutions

N/A

$10.00

Edison Partners

HRS did not outline any specific focuses for its business in the announcement.

HRS offers a broad range of telehealth services that provide systems with real-time monitoring, virtual visits, messaging, patient engagement and education, image transfer and other remote care features.

Q3

CareVoice

Series A

$10.00

LUN Partners Group, unnamed fintech fund, DNA Capital, SoSV and Artesian Capital

CareVoice is investing in platform R&D, expanding its sales teams and launching 10 new health insurtech products.

CareVoice partners with insurers to provide a mobile-based, SaaS cost comparison tool to insurance plans’ members.

Q3

Remedy

Series A

$10

Santé Ventures

The funding will scale Remedy’s technology and expand its offerings for self-funded employers.

Remedy provides both video conferencing with clinicians and house calls through an app. The service is able to treat common aliments like the cold, flu, pink eye, rashes and bronchitis. Patients are also able to get their prescription refills for medications such as birth control, antidepressants and cholesteral medications through the platform.

Q2

Medically Home Group

Series B

$10

Cardinal Health, other unnamed investors

Medically Home will use the funding to scale its at-home care model for more providers and other customers.

The company pitches its “Virtual Hospital” service as an alternative to lengthy and expensive hospital stays. It deploys monitoring and communication tools in the patient’s home, and supports them with its network of rapid-response clinical and non-clinical services that can deliver medications, equipment and other supplies on demand.

Q2

SonarMD

Series A

$10

BCBS Venture Partners and Arboretum Ventures

The company plans to use the funding to scale the business. In particular, they intend to hire additional team members.

The company provides a care management service for chronic conditions.

Q1

Kaia Health

Series A

$10

Balderton Capital

The new money will be used to help the German company expand further into the US.

Kaia employs AI and machine learning to create home-based, clinically-validated exercise plans for users.

Q1

Eden

Series A

$10

Greycroft, PJC, 645 Ventures, Max Ventures, Convene, Aspect Ventures and Brand Foundry

The most recent raise will let the company expand virtual care to all 50 states.

Eden focuses on providing primary care and insurance navigation directly to employers. The company uses a three-pronged approach: Users can access a doctor through a virtual care model, they can use the platform to navigate their insurance benefits, and access Eden’s in-person component in select locations.

Q1

Vicarious Surgical

N/A

$10

Gates Frontier, Khosla Ventures, Innovation Endeavors, AME Cloud Ventures and Marc Benioff

The money will go towards the next phase of growth and developing the commercial product.

The company said that by using its VR and surgical robotic technology, surgeons are able to perform a minimally invasive surgery via a micro-incision.

Q1

MyHealthTeams

Series B

$9.44

Adams Street Partners, Qiming US Ventures, CVS Health, The Westly Group, HealthTech Capital and 500 Startups

The new money will be put toward growing the network and expanding the platform.

MyHealthTeams is a social network designed to help patients with chronic conditions share resources and connect.

Q3

Onera Health

Series A

$9.30

Jazz Pharmaceuticals, imec.xpand, imec, BOM and other unnamed investors

Although the company did not say specifically how it would be channeling its new funds, the announcement did mention upcoming pilot programs.

Onera’s in-development diagnostic platform is centered on disposable monitor patches. The product is pitched as an alternative to bulky clinical sensors, as the patches are unobtrusive and can be applied and worn at home.

Q2

NextGen Jane

Series A

$9

Material Impact, Access Industries, Viking Global Investors, Liminal Ventures and unnamed angel investors

The company plans use the new money to continue its scientific data set and get it on track for a 2020 commercialization date.

The Oakland, California-based startup uses tampons in order to tell women about their reproductive health. The company, which is yet to be launched, is still collecting its clinical data set.

Q2

Tyto Care

Series C

$9

Sanford Health, Itochu and Shenzhen Capital Group

The new funding will allow Tyto Care to continue pursuing plans for growing its telehealth business, which include expansion into Asian and European markets.

Tyto Care offers a remote consultation service, which it supports with a number of devices that are designed to better enable these virtual visits.

Q1

Inne

Series A

$8.89

Blosson Capital, Monkfishy Equity and individuals

The startup has obtained certification as a medical device for their offering in Europe. Inne is expected to release more information about studies carried out to assess its efficacy ahead of launch.

“To use Inne, the woman takes a daily saliva sample on a strip and places it into the Inne reader. The app will collect and calibrate progesterone levels, enabling it to build up a picture of whether the user is fertile that day,” founder Eirini Rapti said.

Q4

Future

Series A

$8.50

Kleiner Perkins

Future will be targeting new business partnerships, expanding its go-to-market strategy and building up its trainer operations with the new funding.

Future pairs consumers with a remote personal fitness coach that will provide weekly training plans that can be adjusted to the individual’s lifestyle. These coaches can check in on users’ smartwatch to ensure that they are following their plans, encourage them through texts, and offer nutrition and lifestyle guidance through the app.

Q2

Covera Health

Series A

$8.50

Equity Group Investments and other undisclosed investors

Covera intends to invest in growth, research and development. The company plans to grow its current team of 40 employees to around 70, and to improve the state of the science to help serve existing customers better and bring additional customers onboard.

Covera Health uses data analytics to help its payer and employer customers choose the best providers and procedures for their members. But unlike many companies in that space, they also work with providers to help them improve their quality.

Q1

BrainCheck

Series A

$8.00

S3 Ventures, Tensility Venture Partners, True Wealth Ventures and Nueterra Capital

The company plans to use the new funding to deepen its engagement with physician groups and with the enterprise healthcare market.

BrainCheck offers software — for iPhones, iPads and desktop computers — that administers a digital version of pen and paper tests for cognitive function.

Q4

Tivic Health Systems

seed funding

$8.00

Sand Hill Angels, Astia Angels, Golden Seeds, HBS Angels, Sierra Angels, Lateral Capital and Skylight Investments

The new money will fuel a marketing push for the ClearUP device’s upcoming launch.

Tivic’s primary product, the ClearUP Sinus Pain Relief device, is a non-invasive, over-the-counter treatment for hay fever sinus pains.

Q3

Kaia Health

Series A/B

$8.00

Optum Ventures

The new money will be put towards developing and scaling the technology.

Kaia Health got its start with a digital physical therapy platform for back pain, which guides users through exercises at home. However, it has quickly expanded to include everything from exercise and wellness tools to programs aimed at treating COPD symptoms.

Q3

Sword Health

Series A

$8

Khosla Ventures and unnamed angel investors

Sword Health will pursue further clinical validation, product improvements and new business within North America.

Sword Health provides tech-enabled physical therapy with a particular focus on musculoskeletal (MSK) disorders.

Q2

Physera

Series A

$8

BlueCross BlueShield Venture Partners

Physera did not provide any clear indications of its future direction outside of general scaling and ongoing updates to the program.

Physera’s free Android and iOS app offers users a range of exercises designed to reduce MSK pains, each of which is demonstrated with in-app animations, voice prompts and other guidance.

Q1

Rightway Healthcare

Series A

$8

Undisclosed

This new funding will fuel sales team growth, product expansion and entry into new markets.

Rightway Health develops a smartphone and web service that helps employees understand and utilize the health benefits available to them. It combines guided navigation and cost transparency tools with live support from staffed navigators.

Q1

Neuroflow

Series A

$7.50

Builders VC, Dreamit Ventures, Spring Point Partners, Red & Blue Ventures and AWT Private Investments

The Philadelphia-based startup plans on putting the new funds towards building its team and investing in product “integrations and data science.”

NeuroFlow uses a multi-pronged approach to treating behavioral health. Patients can tap into digital support tools and additional resources, while providers can use the platform for care coordination.

Q4

FIGUR8

Seed funding

$7.50

P5 Health Ventures and E14 Fund

The new funding will be put towards supporting the technology’s launch.

FIGUR8’s digital platform is designed to measure and track body movements as a biomarker.

Q3

Thriva

Series A

$7.30

Pembroke VCT and Guinness Asset Management

The company did not specify how they would use the money.

Thrivia is a London-based platform providing mail-order blood tests for consumers.

Q3

Florence

Series B

$7.10

Fulcrum Equity Partners, Atrium Health and Bee Partners

The company is currently working on improving digital connectivity within its network. It also wants to make new hires and introduce additional offerings.

Florence Healthcare has been focused since 2014 on bringing clinical trial management into the cloud with its flagship product, eBinders. eBinders includes support for remote patient monitoring, project management and electronic signatures, and is interoperable with electronic medical records and clinical trial management systems.

Q4

Risalto Health

N/A

$7.00

Health Catalyst Capital Management

In addition to funding improvements to the platform itself, Risalto said that these new dollars will help scale the digital musculoskeletal program across the nation.

he New York-based company use artificial intelligence to find muscular and skeletal health providers in the user’s area. Patients navigate these selections through the company’s app, which acts as a digital concierge that helps select prompt, appropriate care for their condition.

Q4

Cara Care

Series A

$7

Johnson & Johnson, Asabys Partners, Atlantic Labs

The company will be carrying out additional research and expanding its footbprint through new partnerships.

Cara Care has developed a mobile app aiming to help people affected by digestive health issues manage their symptoms.

Q2

QTC Care

Series A

$7

Tencent and other unnamed investors

The funding will mainly be used for the development of Digital Therapeutics (DTx) and building medical network to service insurance companies.

QTC Care is a healthcare platform that uses AI to streamline treatment recovery and disease prevention.

Q2

Cynerio

N/A

$7

Accelmed, RDC, MTIP and other unnamed global venture capitalists.

The latest investment would help the security company expand its operations to healthcare providers in North America.

The Ramat Gan, Israel-based company develops a cybersecurity platform designed specifically for healthcare providers.

Q1

DEARhealth

Series A

$6.80

Philips Health Technology Ventures, Vesalius Bio Capital lll and Health Innovations

The new money will be used to help expand its service in Europe and open its European headquarters in Amsterdam.

DEARhealth’s technology uses AI to help clinicians come up with a care plan for patients. The platform is able to integrate with EHR systems and pinpoint subpopulations for specific care.

Q3

Medbelle

Series A

$6.80

signals Venture Capital, Talis Capital, Mutschler Ventures, IBB Beteiligungsgesellschaft and Cavalry Ventures

The new capital will fuel development of the platform while growing the company’s operating footprint.

Medbelle describes its offering as a “three-layered digital hospital” that puts patients in charge of their care and helps them navigate care through digital tools.

Q2

Mightier

Series A

$6.60

Foxkiser, Asset Management Ventures and FundRx, Founder Collective, Slow Ventures and Project 11

The company is raising money to expand its team, specifically in the areas of product development, marketing and engineering.

Mightier offers 25 bioresponsive mobile games, as well as a heart rate monitor (the Mightier Band). The games are designed by popular mobile game developers, but they’re designed to both teach and test emotional regulation skills like deep breathing and visualization. Success at emotional regulation is tied to success in the game.

Q2

PeerWell

Series A

$6.50

OMERS Ventures and Xseed Capital

The money will be put towards launching the company’s new compensation surgery optimization platform.

Before a surgery, patients can log in to PeerWell’s PreHab, a pre-surgery platform that gives patients lessons and advice about their condition. After surgery patients can access ReHab, which helps supplement in-person physical therapy sessions and gives patients additional information about their condition.

Q3

First Stop Health

N/A

$6.50

Morningstar founder and CEO Joe Mansueto as well as Rich Gallun, cofounder and CEO of bswift

The company said it will use the latest funding to grow the services.

First Stop Health is a virtual care provider that targets the employer marketplace, and aims to help employers save money.

Q1

Altoida

Series A

$6.30

M Ventures, Grey Sky Venture Partners, VI Partners AGG, Alpana Ventures and FYRFLY Ventures

The new influx of cash will be put towards commercializing the product in the US and European markets.

Altoida makes a digital platform that employs AI, ML and augmented reality to “collect functional and cognitive biomarkers to help detect Alzheimer’s disease.” The product, which has both an FDA clearance and a CE mark, is meant to detect cognitive decline early on.

Q2

Tasso

Series A

$6.10

Vertical Venture Partners, TechStars and Cedars Sinai

The funding will be used to scale Tasso OnDemand in preparation for its Q2 2019 launch. The startup reports significant commercial interest, and intends to use some of the funding to hire additional employees.

Tasso’s first product, Tasso OnDemand (previously known as Hemolink), is a blood collection device that can be mailed to the patient, used at home, and transmit the data directly to a lab for processing. Rather than using a needle, the patient collects the blood through a patch worn on their forearm, which can be configured to collect whole blood, plasma, or dried blood spots.

Q1

Sleep Data

N/A

$6.00

HCAP Partners

The new cash will be put towards testing and commercializing its product.

BetterNight is a digital tool catered to people with sleep apnea, insomnia, anxiety, jet lag, stress and other sleep conditions.

Q4

Pops! Diabetes Care

Series A

$6.00

30Ventures, Rise of the Rest Seed Fund and Flying Point Industries

The company said the new cash will go towards commercializing the Pops! one System.

Pops! Diabetes Care makes a smart glucometer that employs an algorithm to give users real-time personalized diabetes coaching.

Q3

Baze

Series A

$6.00

Nature’s Way

Baze plans to build out its marketing to promote the benefits of individualized nutritional supplements among consumers.

Baze is a subscription platform that ships personalized vitamin supplement packages.

Q3

GoCheck

Series B

$6

FCA Venture Partners, Mucker Capital and Sovereign’s Capital.

GoCheck will be focusing on additional EHR integrations and new artificial intelligence capabilities that leverage Apple’s CoreML and ARKit, according to the announcement.

GoCheck offers FDA-registered software for Apple and Nokia smartphones that allows pediatricians and other healthcare professionals to screen children aged 6 years and younger for amblyopia.

Q2

BabyScripts

Strategic funding

$6

Royal Philips,StartUp Health and NueCura Partners

The money will allow Babyscripts to begin its push toward the western side of the country.

Babyscripts’ platform offers providers a digital patient management dashboard with data collected through connected devices such as scales, blood pressure cuffs, and a patient mobile app.

Q1

Emedgene

N/A

$6

OliveTreeVentures

The new financial support will be used to expand its sales operations within the US.

Trained using data from patient cases, publications and genomics databases, Emedgene’s decision support engine can identify and highlight clinically relevant genetic variants for the provider.

Q1

TransformativeMed

Series A

$5.80

Alliance of Angels

TransformativeMed will be looking to ramp up its sales and marketing, with the ultimate goal of expanding the country-wide reach of its CORES Value Suite product.

Built for use within Cerner hospitals, the company’s CORES Value Suite product platform inserts a handful of clinical workflows for different specialties or conditions into the EHR.

Q2

AliveCor

N/A

$5.78

 

The company has yet to announce how the new funds will be used, or who the investors are.

AliveCor focuses on single- and six-lead smartphone ECGs and artificial intelligence-based reading interpretations. Its latest product, a six-lead ECG device, was launched in June of this year.

Q4

FundamentalVR

Series A

$5.67

Downing Ventures, Tern PLC, Epic Private Equity and Brighteye Ventures

The latest funding will be put towards growing the company’s Fundamental Surgery platform.

FundamentalVR’s surgical training platform combines VR and haptic sensors. These allow the user to receive physical feedback during a training procedure that better simulates the feel of actually performing the operation.

Q4

Wave

seed funding

$5.65

CrossLink Capital, Lerer Hippeau Ventures, Collaborative Fund and Ludlow Ventures

The company did not outline specific plans.

Wave is a subscription app and connected foam cushion for at-home meditation.

Q3

Oska Wellness

N/A

$5.50

GlobalLink1 Capital, Falls Angel Fund, individual investors

The new money will be put towards its sales, marketing and distribution effots. Additionally, it will also be used to help develop the technology.

The California-based startup developed a device to help pinpoint and reduce a user’s pain. Using pulsed electromagnetic field therapy, the wearable device emits precise frequencies to the user’s pain point.

Q2

MedCrypt

Series A

$5.30

Section 32, Eniac Ventures and Y Combinator

MedCrypt is looking to expands its sales and engineering teams while continuing to develop its software product.

MedCrypt sees an opportunity in contracting with the device makers early on to support new or upcoming products. Its software product covers any medical device that has a computer processor, and meets the cybersecurity regulations and recommendations recently stressed by the FDA.

Q2

B-Secur

Series A

$5.30

Accelerated Digital Ventures and Kernel Capital

The latest funding round will go toward creating new partnerships, similar to existing deals with Cypress Semiconductor and NXP Semiconductors. Additionally, the company plans to add at least 10 new employees to its 35-person team and to open up an American office in San Francisco.

B-Secur is looking to use ECG monitoring in a dual role: both for health and wellness purposes and for biometric identification. The potential use cases include helping employers monitor their users’ health while also securing protected areas, or creating security systems for vehicles that would also detect, via the steering wheel, when drivers are stressed out or in need to rest.

Q1

Vital

Seed funding

$5.20

First Round Capital, Threshold Ventures, Bragiel Brothers, Meridian Street Capital, Refactor Capital and SV Angel

The funding announcement is timed with the public launch of the company, and will support four hospital rollouts and additional sales efforts.

Vital is offering a patient and clinician-facing AI software for emergency rooms that, while not replacing the EHR (notably the software isn’t designed for billing), aims to replace the EHR’s user experience as much as possible.

Q2

Roundtrip

Series A

$5.10

Motley Fool Ventures, Ben Franklin Technology Partners of Southeastern Pennsylvania, Johns Hopkins University and an unnamed medical device company

The company is looking to build out its software capabilities and more than double its current pool of employees.

Roundtrip software allows healthcare professionals to order and coordinate patients’ medical transport using a pool of available ride providers, whether they be Lyft drivers, facility-owned vehicles, volunteers or otherwise. The platform is available online and as a mobile app, and includes interfaces for providers and patients alike.

Q2

Savonix

Series A

$5.10

Fusion Fund, Wavemaker Partners, DEFTA Partners, Rethink Impact and DigiTx Partners

The funding will be used to build out the technology, though the company isn’t sharing too many details on specific features yet.

Savonix’s flagship app, Savonix Mobile, is a 30-minute brain training and testing app based on existing clinical guidelines and procedures.

Q2

Emilio Health

Seed funding

$5.00

Oak HC/FT

This new money will be put towards opening Emilio’s first clinics, launching its digital platform and growing its leadership team.

Emilio’s services will include brick-and-mortar clinics with specialty services including occupational therapy and behavioral specialists. The startup is also incorporating a digital platform, which can be used to help track progress, schedule appointments and access tele-therapy.

Q4

Dadi

investment funding

$5.00

TCG, Capital and Third Kind Ventures

The new funding will help expand its customer services capabilities, which include more fertility education and customer support.

Dadi is a direct-to-consumer male fertility testing and sperm storage startup.

Q3

MedAnswers

 

$5.00

Special Situations’ Life Sciences Innovation (LSI) Fund and Viking Global Investors

The new money will be used to continue the rollout of FertilityAnswers.

The company’s product FertilityAnswers emulates a social media feed, but its goal is to help consumers trying to conceive view clinically validated expert information.

Q3

Astarte Medical

Series A

$5

Viking Global Investors, Lunsford Capital, OCA Ventures, Keiretsu Forum MidAtlantic, Keiretsu Capital Fund, Ben Franklin Technology Partners, Wing VC and Next Act Fund

The investment will be used to complete the development of NICUtrition.

Astarte is building a suite of tools for the neonatal intensive care unit (NICU) called NICUtrition. The software suite will be built on a proprietary database of feeding protocols, microbial profiles and clinical information which will power predictive analytics that can advise care teams on protocols and treatment plans.

Q2

BetterPT

Series A

$5

5Lion Ventures, Hospital for Special Surgery and ID Fund

 

The company plans to use the new money to grow its geographical reach, as well as user adoption.

Q2

ExplORer Surgical

Series A follow on

$5

Aphelion Capital, prior investors and new unnamed backers

The company will be looking to build up its user base and introduce new features to the platform.

ExplORer Surgical’s provider-facing platform looks to help surgical teams better coordinate tasks or instrumentation. The “digital playbook” provides info on which instruments or supplies to use in the moment, while recording which tools are used for the organization to review.

Q2

Jio Health

Series A

$5

Monk Hill’s Ventures

The new funds will be used by Jio Health to scale its operations and capabilities across Vietnam.

The startup currently operates an online healthcare app (available on iOS and Android platforms) and a physical facility in Saigon. It provides on-demand access to healthcare services such as primary care, chronic disease management, pediatrics and ancillary care services.

Q2

Biolinq

Series A

$4.75

JDRF T1D Fund

The company said that the new money will be put towards growing its technology platform and funding additional clinical studies.

Biolinq makes a minimally-invasive device that lets people continuously monitor their blood glucose. It pitches its technology as an alternative to finger pricks.

Q1

Kindbody

N/A

$4.50

GV

The company plans on using the new cash to geographically expand its services.

This female-led startup uses a hybrid approach to care. It combines face-to-face visits with a virtual care component.

Q4

Sentio

Seed funding

$4.50

Felicis Ventures, Anthemis Exponential Ventures and SOSV

This announcement also marks the launch of the Feel platform, which Sentio is positioning as a service for payer, employer and health system partners. The startup noted that the investment will help drive these partnerships.

Sentio’s Feel platform is headlined by the Feel Emotion Sensor, a wristband that monitors physiological signals such as heart rate, skin temperature and galvanic skin response to inform CBT.

Q4

Fitplan

N/A

$4.50

Corazon Capital, A-Rod Corp, Mark Mastrov, Lerer Hippeau, Bullpen Capital, Imaginary and Advancit Capital

The new funding will go toward further development of the product, and will help Fitplan bring more athletes onto its roster of featured trainers.

The Fitplan app delivers on-demand video workout sessions and exercise tracking to consumers for a monthly or annual subscription. These sessions are headed by one of the company’s dozens of fitness coaches.

Q3

Combinostics

Series A

$4.33

Industrifonden and NordicNinja VC,

The first application of their technology looks at Alzheimer’s disease, and, with the new funding, the startup now wants to bring its cNeuro platform to the US and Asia.

Founded in 2014, Combinostics aims to support healthcare professionals in the diagnosis of neurodegenerative diseases, helping to improve patients’ quality of life.

Q4

Aural Analytics

Seed funding

$4.30

Morningside Ventures, Tamarisc Ventures, Six Street Partners Group managing director Jamie Gates, Marc Abramowitz, Arizona Tech Investors and Desert Angels

These funds will help the company expand its clinical trial platform, as well as release an integration portal for speech collection and analysis alongside other clinical-grade mobile and web products.

The AI engine collects speech samples through a smartphone or tablet app, and uploads these to a cloud server for analysis. From these, the company can generate insights on the speaker’s neurological health, such as Alzheimer’s disease.

Q3

Winterlight Labs

N/A

$4.23

Hikma Ventures, First Star Ventures, Pacific Health Ventures, Grey Sky Venture Partners and others

The Canadian company plans to use the new funds to further develop its product so it can identify more conditions, including schizophrenia and multiple sclerosis. The team also plans to add new languages to the platform.

Winterlight Labs makes a tablet-based technology that employs speech-based artificial intelligence to identify possible cognitive declines or changes in a patient. The tool uses a speech-based assessment to identify vocal biomarkers that are indicators of changes in cognition.

Q4

NexHealth

N/A

$4.20

Point Nine Capital, Rubicon Venture Capital, Scott Belsky, Josh Hannah and iSeed Ventures

Alongside improvements to its product, NexHealth is opening a new office in San Francisco, and as such will be using some of these new funds to staff its new west coast location.

NexHealth offers a tool that helps practices mange their communications and administrative interactions with patients.

Q3

Meru Health

Seed funding

$4.20

Freestyle Capital, Bonit Capital, Y Combinator, Lifeline Ventures and IT-Farm

The startup said the new money will be put towards additional clinical validation and preparations for a larger rollout to health systems and employers.

Meru offers a digital mental health tool that is supported by licensed therapists. The program lasts 12 weeks, and each week has a different theme that builds on the previous one.

Q2

DynamiCare Health

Seed funding

$4.10

Hyperplane Venture Capital, former US Representative Patrick J. Kennedy and other unnamed investors

DynamiCare plans to use its new millions to launch a consumer version of its app within the coming months, as well as to upgrade its telehealth coaching services.

DynamiCare Health has built a platform supports users’ substance use disorder recovery with a number of smartphone-based features.

Q2

NOCD

Series A

$4.00

Chicago Ventures, 7Wire Ventures, Meridian Street Capital and Hyde Park Angels

The startup said it will be using these new funds to expand its NOCD Provider Network across the US.

NOCD’s app features a range of self-help tools such as evidence-based exposure and response (ERP) exercises, user forums for sharing and discussing symptoms and immediate guidance on tolerating discomfort for unexpected compulsion episodes and other OCD education.

Q4

Genneve

N/A

$4.00

BlueRun Ventures. Maven Ventures and Startup Health

The company will be using its new funding to expand its service from 23 states to 50 by the end of the year.

Genneve provides an online telehealth service serving women experiencing menopause.

Q3

metaMe Health

seed funding

$3.80

LionBird Ventures led the round, which also saw contributions from Hemi Ventures and other unnamed backers

The seed funding will support continued development of the digital product, particularly through the initiation of a large, randomized controlled trial of IBS patients.

The startup creates behavioral digital treatments for gastrointestinal conditions.

Q3

Unmind

N/A

$3.80

Felix Capital and private investors

The latest funding round will be put towards improving the mobile platform and increasing its library of contents.

The London-based startup focuses on promoting mental health in the workplace. Specifically, the company works with employers to provide digital tools to their workforce. The company stresses that it has worked with academics and psychologists to develop the training tools and assessments.

Q1

Embleema

Series A

$3.70

Pharmagest and Techstars

The company will accelerate the joint development of blockchain-based applications for patients and pharmacies. It will also help the company kick off its commercial deployment.

The company uses blockchain technology, which makes information easy to verify and difficult to falsify, to build a personal health record system for patients. The startup was designed to help patients share their blockchain health records and data with stakeholders, such as clinical researchers, in exchange for cryptocurrency.

Q1

Infermedica

N/A

$3.65

Karma Ventures, Dreamit Ventures, Inovo Venture Partners and Müller Medien​

The company will be launching its service in the US.

Patients using Infermedica’s platform are able to enter their chief complaint into a symptom checker. Using artificial intelligence, the platform will then ask the patient another set of questions.

Q2

Scanwell Health

Seed funding

$3.50

Founders Fund, Mayfield, DCM, Version One, Y Combinator and Liquid 2 Ventures

Scanwell said in its announcement that the new funds would support the national launch of its platform, and help the company hire more staff and develop new diagnostics capabilities for its platform.

Scanwell Health’s claim to fame is its FDA-cleared home urine testing app. Consumers urinate on the low-cost, mail-order test kit and take a photo of the results with the Scanwell app. If the test comes up positive, the company connects users to an in-house physician at low cost who can any necessary antibiotics within a single day.

Q4

Mon Ami

Seed funding

$3.40

Freestyle Ventures, Cowboy Ventures, Maverick Ventures, Felicis Ventures and angel investor Bruce Dunlevie

The company plans to put this new cash toward growing the number of cities the platform caters to as well as further developing the product.

College students can apply through the Mon Ami platform to be a companion for an older person. They are then vetted by the team and matched with a senior based on similar interests and language.

Q4

Podimetric

Series B extension

$3.15

Polaris Partners

Podimetrics will be furthering its businesses with the VA and commercial payers.

Podimetrics’ platform consists of a cellular-connected SmartMat for use in the home, and a corresponding clinician-facing dashboard.

Q4

Diligent Robotics

Seed funding

$3.00

True Ventures, Ubiquity Ventures, Next Coast Ventures, Capital Factory, Pathbreaker Ventures, Boom Capital, Grit Ventures and other unnamed angel investors

This latest round will primarily help Diligent Robotics launch Moxi for hospital customers, but will also support hardware and software product strategy and development, according to the company.

Diligent Robotics’ broad aim is to develop robotic assistants for a range of chores or activities in the hospital.

Q4

Mahmee

N/A

$3.00

ArlanWasHere Investments, Mark Cuban, Serena Williams’ Serena Ventures and Revolution’s Rise of the Rest Seed Fund

Mahmee will focus on building its team of engineers, clinicians and salespeople using its new money.

Mahmee’s tool works within a provider’s IT system to link a mother and child’s health records and help keep the care team coordinated.

Q3

NextStep

N/A

$3.00

SEI Ventures, JAZZ Venture Partners, Learn Capital’s Learn Start Fund, Springrock Ventures, City Light Capital, Frontier Angels and managing directors from Pioneer Square Labs

The company did not specify what the new funds will be put towards.

The Seattle, Washington-based startup focuses on digitally training new healthcare workers, in particular individuals who have lost their jobs because of new technology.

Q3

Karuna Labs

Seed funding

$3.00

Baseline Ventures, Anorak Ventures, the AET Fund, the Hustle Fund, Correlation Ventures and Dreamit Ventures

Karuna said that this funding will support clinical validation studies of its VR product, and help the company further develop its technology and staff.

The company develops personalized VR programs for chronic pain management. The tool uses a technique known as “virtual embodiment training” to help users disassociate body motions with pain.

Q3

NuvoAir

N/A

$3

Inustrifonden and Investment AB Spiltan

NuvoAir plans to use the new money to grow its team, as well as fuel its development pipeline and clinical trials. It is also looking to expand globally.

The company made a name for itself with a smartphone spirometer able to conduct lung function assessments in a home environment.

Q2

Narrative Dx

Strategic funding

$3

Christiana Care Health System, Summation Health Ventures, The Texas Medical Center, HealthX Ventures and Cultivation Capital.

The company plans to use the funds “to accelerate sales and marketing, product innovation, talent acquisition and continued growth.”

arrativeDx uses AI and natural language processing to analyze patient feedback and return suggestions on how a healthcare organization can improve its patient experience. After participating in several accelerators, including DreamIt Health, Cedars-Sinai’s accelerator, and Startupbootcamp’s Digital Health Miami program, the company has found its way into a more than 100 hospitals.

Q1

Elektra Labs

Seed funding

$2.90

Maverick Ventures, Arkitekt Ventures, Boost VC, Founder Collective, Lux Capital, SV Angel and Village Global and 16 angels

The startup said in its announcement that the seed funding will help “improve infrastructure for the efficient and responsible deployment of wearables and connected biosensors.”

Elektra offers Atlas, a catalogue-like digital platform that Elektra says it interviewed more than 300 digital clinical trial stakeholders to design.

Q4

Zero

seed funding

$2.80

True Ventures and Trinity Ventures

The company said it plans to use the new funds to grow the platform and bring new product offerings to market.

The company’s app is centered around helping users bring fasting into their dietary regime.

Q3

OvuSense

Series A

$2.70

Foresight Group and Coutts Investment Club

Fertility Focus said that the funding will be put toward commercialization of the OvuSense platform in North America and European markets, and the funding of new clinical trials of the technology.

OvuSense is comprised of a vaginal core temperature sensor and an accompanying user app.

Q1

Meddy

Series A

$2.50

Modus Capital, 212 Capital, QSTP, Kasamar Holdings, Dharmendra Ghai, Innoway and other unnamed investors

The new cash will be put towards expanding the company’s coverage in UAE. While it currently covers Dubai and Sharjah, the new money is set to help it expand into Abu Dhabi and other emirates.

The platform, which is currently up and running in Qatar and the United Arab Emirates (UAE), allows patients to search doctors that meet their criteria and need. Users can search for general care, such as internal medicine or OB/GYNs and specialty care, such as a urologist or endocrinologist.

Q4

Voro

Seed funding

$2.50

Floodgate, Techstars, Flatiron Health, Tilt, Clover Health, Surion, Teamworthy Ventures, AVG Basecamp Fund, Ride Ventures, OneOncology and others

The startup did not outline any specific uses for its seed funding.

Voro’s “health care social network” looks to inform patients’ care decisions by providing them with direct recommendations from their friends, coworkers or neighbors.

Q3

Giblib

Seed funding

$2.50

Mayo Clinic, the Venture Reality Fund, Wavemaker 360, USC Marshall Venture Fund and Michelson 20MM.

The seed round will help Giblib to build out its offerings technically as well as form additional partnerships and expand the amount of content available in its streaming library.

Giblib works with hospitals to offer a streaming service filled with 4K and 360 degree VR videos of both medical lectures and surgeries.

Q2

Olio

Seed funding

$2.50

Innovatemap Ventures and other unnamed backers

The company said that the new money will be put towards scaling the technology and expanding across the US. The seed funding will also be used to growing its engineering, marketing and customer success teams.

The care coordination platform lets the care team at a hospital including doctors and administrators get information about their patients once they have moved into the post-acute setting. The platform helps clinicians to set speciality-specific care goals and funnels data back and forth.

Q1

1upHealth

Seed funding

$2.38

Eniac Ventures, Social Leverage and Meridian Street Capital

The new money will be put towards scaling the operation and furthering its work on EHR connectivity.

The Boston-based startup lets patients, providers and developers aggregate and share health data — including information from EHRs — through an API. The platform is able to convert esoteric EHRs into the FHIR standards. It also has a patient interface, which lets them authorize connections between their data and provider.

Q1

Child Health Imprints

pre-Series A

$2.30

HealthXCapital, Seeds Capital and other individuals

The freshly raised funds will go towards expanding the startup’s integrated neonatal ICU (NICU) care services in Asia Pacific as well as in securing international regulatory approvals.

CHIL is engaged in the development and application of cutting edge informational and computational technologies including IoT, artificial intelligence and predictive analytics to the practice of medicine in NICUs across the world.

Q4

Closed Loop Medicine

Pre-Series A

$2.30

Longwall Venture Partners, IQ Capital and Martlet

The new funding will underpin the development of a “drug + digital approach” aiming to treat various health conditions, initially looking at hypertension and sleep disturbance.

The Cambridge startup, which describes itself as a “new breed of therapeutics company,” says its approach is based on using data and insights about how patients are responding to treatments to tailor drug and non-drug therapy.

Q2

Primaa

N/A

$2.22

F3A, Entrepreneurs Investis, 50 Partners, Angels Santé and angels.

The funding will accelerate deployement in France and internationally.

Primaa aims to improve on the manual diagnostic process, under which samples are transferred to slides and analysed under the microscope by experts via AI automation.

Q4

Motivo

Seed funding

$2.20

Cox Enterprises, Techstars, SEI Ventures, ECMC, Great Oaks VC, The Jump Fund, Emmett Partners, Next Wave Impact Fund and other unnamed angel investors

Motivo wrote in its announcement that the raise will help the startup expand its staff, pickup contracts from mental health agencies and clinics, and ink new partnerships with professional organizations and academic institutions.

Motivo’s platform matches new therapists and supervisors and, through live video sessions, conducts clinical supervision consultations online.

Q4

BabySparks

seed funding

$2.00

Miami Angels, Kairos, Marstar Investments, Lou Kreisberg and Steve Goodman

The startup plans to use the funds to accelerate and grow the product.

BabySparks has built an app-based tool for parents to track and stimulate the development of their young children.

Q3

TNH Health

Series A

$2.00

Valor Capital Group and unnamed individual entrepreneurs

The new money will go towards promoting the chatbot, as well as expanding internationally to the US.

The startup is focusing on mental health conditions such as anxiety, stress and depression via a chatbot runs in Facebook Messenger, Whatsapp, web channels, SMS and mobile platforms.

Q3

Sentinel Healthcare

N/A

$2

PSL Ventures

Sentinel said it will be putting the new funds toward continued development of its commercial platform.

Sentinel provides a wearable blood pressure cuffs and patient smartphone app that transmit data to the company’s wider service.

Q1

Wefight

N/A

$1.98

Funds secured through the EIT Health Investor Network

Wefight plans to extend its product to a further 33 disease types by 2020.

Wefight’s ‘Vik’ app can answer patients’ questions about their condition, treatment and care pathway. It features services such as smart pill reminders, a notebook to monitor side effects and personalized therapeutic education.

Q3

Shleep

N/A

$1.54

Global Founders Capital and Health Innovations

The funding will help Shleep scale its platform.

With Shleep’s digital sleep coaching platform, users get access to a “sleep expert,” courses, relaxation tools and individual and group consultations, as well as live webinars providing information on how to cope with sleep deprivation and insomnia, among others.

Q3

Give InKind

Pre-seed funding

$1.50

Trilogy Equity Partners, Madrona Venture Group, SeaChange Fund, Keeler Investments, FAM Fund, and Grubstakes, X Factor Ventures and Seattle-area angel investors.

Give InKind said that is interested in further building out the platform and its reach, and will be targeting healthcare groups, churches and other community organizations by developing new strategic offerings.

The Give InKind web tool allows users to create sharable online pages for a number of caregiving situations, ranging from birth to senior care to grief to serious medical events.

Q4

ClinicianNexus

Seed funding

$1.50

Hyde Park Venture Partners, Cedars Sinai, Great North Labs and Sofia Fund

The company will be further building upon its training scheduling platform.

Clinician Nexus builds a platform for medical students and clinicians to better connect, with a focus on rotation scheduling.

Q4

Flow

N/A

$1.50

Khosla Ventures

The new funding will be put toward rolling out the product in Europe.

Flow is a two-part system including a brain stimulation headset and a therapy app.

Q3

Vixiar

Series A

$1.50

Emerald Development Managers, MMG Opportunities, The Maryland Technology Development Corporation (TEDCO), unnamed individuals

The company will use the funding to complete an ongoing clinical trial of Indicor and to prepare a regulatory submission.

Vixiar’s first product, Indicor, is a hardware and software system for measuring left ventricular end-diastolic volume, which can be used to calculate stroke volume, an important biometric for monitoring some heart conditions. It consists of a tablet, a pulse oximeter and a handheld device with a disposable mouthpiece.

Q1

Pr3vent

Series A

$1.50

InFocus Capital Partners

Cofounder Darious Moshfeghi said in a statement that the new backing will allow his company to “accelerate the process of developing our revoluationary imaging system for early detection of preventable vision loss in newborns.”

Pr3vent is building artificial intelligence and machine learning-based screening tools specifically tuned to detect ophthalmic conditions in newborns. The screens are not invasive, and seek to identify and address abnormalities early in a child’s development so that future blindness can be prevented.

Q1

Vine Health

seed funding

$1.47

Playfair Capital

The new cash will be put towards growing the team and developing the platform.

The company’s aim is to help cancer patients manage their condition and symptoms through an app.

Q3

Feebris

Seed funding

$1.40

Innovate UK and 24 Haymarket

The investment will support Feebris’ AI-enabled platform to continue bridging the gap between the community and providers across a range of respiratory conditions including pneumonia, COPD and asthma.

The British startup is focused on using artificial intelligence to identify physiological markers that put a patient at-risk of deteriorating.

Q2

OncoLens

Seed funding

$1.35

BIP Capital and Atlanta Technology Angels (ATA)

The new money is expected to help the company fulfill its strategic growth plans.

The Atlanta-based company focuses on giving cancer care teams a way to collaborate on patients’ treatment plans. The software-as-a-service tool, which includes a mobile application, is cloud based and HIPPA compliant.

Q1

Blueprint

N/A

$1.30

Lightbank and Hyde Park Angels

Blueprint will be using its new funding to beef up its engineering and sales teams while expanding clinician outreach.

Blueprint’s app-based platform distributes standardized clinical assessments to patients and automatically logging behavioral factors such as sleep or exercise with the smartphone’s sensors.

Q2

Enable My Child

Seed funding

$1.20

CMI Ventures

The money will help Enable My Child expand its virtual services for school and early intervention centers across the country.

The company is focused on connecting children with behavioral, learning or developmental conditions to a variety of board-certified therapists for tele-therapy. The services include virtual occupational therapy, speech therapy, physical therapy and psychology services.

Q3

UpLift Health

seed funding

$1.00

Laidir Foundation

The recent investment will be put towards developing the company’s technology.

The Atlanta-based startup has created an app that employs cognitive behavioral therapy (CBT) to help users with depression.

Q3

RocketBody

N/A

$1.00

Gagarin Capital and AltaIR Capital

The new funds will be used to improve user retention and hammer out the monetization of its app.

RocketBody has released an Apple Watch app that uses the onboard ECG sensor and AI to guide fitness and training recommendations.

Q3

iWEECARE

Pre-Series A

$1

Verge HealthTech Fund, Translink Capital and Darwin Venture

The company will support its flagship product, Temp Pal.

The company’s Temp Pal product is a comprehensive and convenient wireless body temperature tracking solution that offers real-time monitoring combined smart alerts, seeking to disrupt a market forecasted to reach $1.5B by 2025 currently dominated by digital pen and in-ear thermometers.

Q2

Feedtrail

Seed funding

$1

Dioko Ventures and an unnamed non-profit health system

Feedtrail plans to use the new money to hire sales and marketing staff. It will also be put towards scaling the platform.

Founded in 2015, the North Carolina-based startup specializes in phone-based patient satisfaction surveys. The platform then is able to analyze these survey results and give providers feedback based on where they are falling short. It also gives providers possible strategies and methods that could help solve any logistical issues.

Q2

OOVA

Seed funding

$1

Special Situations Life Sciences Innovation Fund, Company Ventures and angel investors

The funding will help the company make its final push into the market.

The company’s first product, which is currently in pre-orders, is a mail-order test kit for fertility monitoring that contains 20 disposable urine tests. The tests can be scanned with a smartphone to get results directly on the user’s phone.

Q1

Nori Health

Pre-seed funding

$0.68

Unnamed angel investor

 

Nori has developed and tested a chatbot for people with inflammatory bowel disease.

Q2

RelayOne

Seed funding

$0.50

Cofounders Capital

RelayOne use the new funding to launch its software.

RelayOne has created a secure software platform that disseminates that scheduling information to all the relevant stakeholders in real time. It works with EHRs and is designed to be HIPAA-compliant.

Q2

SafeKeeping

Seed funding

$0.33

Solidea Capital and other unnamed investors

The funding will allows SafeKeeping to expand its team, platform and client reach.

SafeKeeping’s integrated communication tool aims to cut down on non-emergency calls between care teams and patient families.

Q3

Mightier

Series A

$0.25

Modern Time Group

The new money and partnership with MTG will go towards adding more tools for users.

Mightier’s program includes 25 bioresponsive mobile games and a special heart rate monitoring band. The games are aimed at help children learn coping skills like deep breathing and visualization.

Q3

Fitt

N/A

undisclosed

Mountain State Capital, Riverfront Ventures, TNC Ventures and MINDBODY

Fitt noted that the funding will fuel new reader content, covered locations and additional features for the company’s platform.

Fitt’s primary web and mobile platform was founded in 2017 as a way to provide health and fitness coverage or recommendations that are localized to a reader’s location.

Q4

Omada

Strategic investment

undisclosed

Intermountain Ventures

“We’ll leverage this investment to accelerate the expansion of the company’s integrated digital care program, as well as deepen our collaborations with Intermountain, aiming to bring patients the very best in digital care,” CEO Sean Duffy said.

Omada pitches its digital coaching programs as a scalable and convenient approach to chronic disease management. The company’s products address hypertension, Type 2 diabetes, mental health conditions and other health needs.

Q4

Mika

N/A

undisclosed

Ananda Impact Ventures and VC Fonds Technologie Berlin

The funds will support a clinical study and further app development.

Mika has developed an app to support cancer patients and their families, in collaboration with the Charité university hospital in Berlin and University Hospital Leipzig.

Q3

Medly

Series A

undisclosed

Greycroft

The startup said it plans to use the infusion of funds to help it expand its services nationally.

The New York City-based startup provides same-day delivery of a patient’s prescription medication. A patient can have their provider send their prescriptions to the Medly platform.

Q2

Theranica

Series B add-on

Undisclosed

Omron Ventures

Theranica said in March that its current round will support mass production of its Nerivio Migra device.

Theranica is a biomedical technology company focused on developing advanced electroceuticals for migraine and other prevalent diseases.

Q2

Medigo

Seed funding

Undisclosed

Venturra Discovery

Medigo is running a pilot of its product.

The startup focuses on connecting healthcare facilities with the mission to “build a better, more connected Indonesian digital healthcare ecosystem.”

Q2

Forefront Telecare

Series A

undisclosed

Spring Lake Equity Parnters, Ziegler Link Age Fund

Forefront will put the new money toward growing its network of telepsychiatry providers and developing HIPAA-compliant telehealth platforms.

Forefront Telecare specializes in providing virtual behavioral telehealth to seniors.

Q1

Workit Health

Series A

undisclosed

BlueCross BlueShield Venture Partners

As a result of the funding, Workit Health will be teaming up with Blue Cross Blue Shield Ventures.

Workit Health provides online addiction treatment to patients recovering from opioid use.

Q1

Echelon Fitness Multimedia

N/A

undisclosed

North Castle Partners

The investment will help Echelon Fit increase the availability of its existing and upcoming products in North America.

The startup offers an in-home connected workout experience similar to Peloton; however, customers can connect the bike to their own t

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top
Make Money